Asia Pacific Hydrocephalus Shunts Market
Asia Pacific Hydrocephalus Shunts Market is growing at a CAGR of 3.7% to reach US$ 82.49 million by 2028 from US$ 66.26 million in 2022 by Age Group, Type, Product, and End User

Published On: Jan 2023

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Asia Pacific Hydrocephalus Shunts Market

At 3.7% CAGR, the Asia Pacific Hydrocephalus Shunts Market is projected to be worth US$ 82.49 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific hydrocephalus shunts market was valued at US$ 66.26 million in 2022 and is expected to reach US$ 82.49 million by 2028, registering a CAGR of 3.7% from 2022 to 2028. Increasing prevalence of hydrocephalus and increasing advancement in hydrocephalus valves are the critical factors attributed to the market expansion.

Cerebrospinal fluid (CSF) in the brain and spinal cord protects the central nervous system from injury and infection. The accumulation of excess CSF in brain cavities adds to intracranial pressure, thereby leading to hydrocephalus. The condition may further lead to macrocephaly and cognitive dysfunctions. Hydrocephalus is more prevalent in children and infants than adult population. The treatment approach of hydrocephalus highly focuses on managing CSF through medical devices named shunts. The shunt systems remove excess cerebrospinal fluid from the brain and divert it to other body parts, wherein it is absorbed as a part of the circulatory process. Thus, the high incidence of hydrocephalus leads drives the demand for hydrocephalus shunts, thereby boosting the Asia Pacific hydrocephalus shunts market growth.

On the contrary, high cost of treatment due to shunts and revision surgeries hampers Asia Pacific hydrocephalus shunts market. 

Based on age group, the Asia Pacific hydrocephalus shunts market is segmented into pediatric and adults. The pediatric segment held 56.8% market share in 2022, amassing US$ 37.65 million. It is projected to garner US$ 47.18 million by 2028 to expand at 3.8% CAGR during 2022–2028.

Based on type, the Asia Pacific hydrocephalus shunts market is segmented into ventriculo-peritoneal, ventriculo-atrial, ventriculo-pleural, and lumbo-peritonea. The ventriculo-peritoneal segment held 45.1% market share in 2022, amassing US$ 29.85 million. It is projected to garner US$ 37.88 million by 2028 to expand at 4.0% CAGR during 2022–2028.  

Based on product, the Asia Pacific hydrocephalus shunts market is segmented into hydrocephalus valves, hydrocephalus catheters, neuronavigation systems, and others. The hydrocephalus valves segment held 61.5% market share in 2022, amassing US$ 40.72 million. It is projected to garner US$ 51.35 million by 2028 to expand at 3.9% CAGR during 2022–2028.  

Based on end user, the Asia Pacific hydrocephalus shunts market is segmented into hospitals, ambulatory surgical centers, others. The hospital segment held 56.0% market share in 2022, amassing US$ 37.09 million. It is projected to garner US$ 47.29 million by 2028 to expand at 4.1% CAGR during 2022–2028.     

Based on country, the Asia Pacific hydrocephalus shunts market has been categorized into China, India, Japan, Australia, South Korea, and the Rest of Asia-Pacific. Our regional analysis states that China captured 30.8% market share in 2022. It was assessed at US$ 20.40 million in 2022 and is likely to hit US$ 26.20 million by 2028, exhibiting a CAGR of 4.3 % during the forecast period.            

Key players dominating the Asia Pacific hydrocephalus shunts market are B. Braun Melsungen AG (CHRISTOPH MIETHKE GMBH & CO. KG); HpBio Próteses, inc.; Integra LifeSciences Holdings Corporation; KANEKA MEDIX CORP.; Medtronic; Natus Medical Incorporated; and Spiegelberg GmbH & Co. KG, among others.

  •  In July,2019; Integra LifeSciences announced the acquisition of Arkis Biosciences Inc. a privately-held company that offers a portfolio of neurosurgical devices such as catheters. The acquisition of Arkis Biosciences strengthened Integra’s offerings in neurocritical care and Integra’s position as the world leader in advanced catheter technology.
  • In May,2020; Aesculap, Inc. in partnership with The Christoph Miethke GmbH & Co. KG (MIETHKE) announced the launch of the M.blue valve in the US. The M.blue valve features advanced gravitational technology, which is incorporated with a fixed differential pressure unit in one valve. It helps to provide a simple and position-dependent solution.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com